TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›AVXL›Financials
Annual statements · SEC XBRL · FY2016 – FY2025

ANAVEX LIFE SCIENCES CORP. (AVXL) financials

Income statement

ANAVEX LIFE SCIENCES CORP. (AVXL) income statement, annual, from SEC filings
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income————-$31.1M-$42.0M-$51.0M-$55.8M-$52.9M-$51.4M
Net income-$14.7M-$13.5M-$17.3M-$26.3M-$26.3M-$37.9M-$48.0M-$47.5M-$43.0M-$46.4M
EPS (diluted)-$0.42-$0.33-$0.39-$0.54-$0.45-$0.54-$0.62-$0.60-$0.52-$0.54

Cash flow

ANAVEX LIFE SCIENCES CORP. (AVXL) cash flow, annual, from SEC filings
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$9.24M-$9.02M-$12.6M-$18.5M-$21.3M-$30.4M-$24.2M-$27.8M-$30.8M-$39.0M

Balance sheet

ANAVEX LIFE SCIENCES CORP. (AVXL) balance sheet, annual, from SEC filings
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$9.19M$27.4M$22.9M$22.2M$29.2M$152M$149M$151M$132M$103M
Total assets$9.50M$27.8M$26.2M$25.3M$34.5M$162M$153M$154M$136M$104M
Total liabilities$3.19M$3.58M—$5.04M$7.31M$10.8M$10.2M$12.5M$15.3M$8.95M
Shareholders' equity$6.31M$25.9M$22.3M$20.3M$27.2M$151M$142M$142M$120M$94.9M
Retained earnings-$78.0M-$89.8M-$107M-$133M-$160M-$198M-$246M-$293M-$336M-$382M
Shares (wtd avg diluted)35.2M43.3M45.9M52.7M62.0M69.8M76.9M79.8M83.5M85.3M

Every figure is extracted from ANAVEX LIFE SCIENCES CORP.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

Does AVXL pay a dividend?
ANAVEX LIFE SCIENCES CORP. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full AVXL analysis — verdict, score & filings →Is AVXL a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.